| 000 | 01676 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517130338.0 | ||
| 264 | 0 | _c20171106 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a1473-5741 | ||
| 024 | 7 |
_a10.1097/CAD.0000000000000460 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShiozawa, Nobuya | |
| 245 | 0 | 0 |
_aInhibitory effect of a redox-silent analogue of tocotrienol on hypoxia adaptation in prostate cancer cells. _h[electronic resource] |
| 260 |
_bAnti-cancer drugs _c03 2017 |
||
| 300 |
_a289-297 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdaptation, Physiological _xdrug effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aBasic Helix-Loop-Helix Transcription Factors _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCell Hypoxia _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoxia-Inducible Factor 1, alpha Subunit _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProstatic Neoplasms, Castration-Resistant _xdrug therapy |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-fyn _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTocotrienols _xpharmacology |
| 700 | 1 | _aSugahara, Ryosuke | |
| 700 | 1 | _aNamiki, Kozue | |
| 700 | 1 | _aSato, Chiaki | |
| 700 | 1 | _aAndo, Akira | |
| 700 | 1 | _aSato, Ayami | |
| 700 | 1 | _aVirgona, Nantiga | |
| 700 | 1 | _aYano, Tomohiro | |
| 773 | 0 |
_tAnti-cancer drugs _gvol. 28 _gno. 3 _gp. 289-297 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/CAD.0000000000000460 _zAvailable from publisher's website |
| 999 |
_c26674184 _d26674184 |
||